Uncategorized
Second phase 3 trial of OTX-DP meets one of two primary endpoints
The second phase 3 trial of OTX-DP did not meet the primary endpoint of absence of inflammatory cells but met the primary endpoint of absence of pain, according to topline data released by Ocular Therapeutix.The trial included 240 patients who were randomized to treatment with OTX-DP (sustained-release dexamethasone 0.4 mg) or a placebo vehicle control punctum plug.